XAF1 as a prognostic biomarker and therapeutic target in pancreatic cancer

Cancer Science

Volumn 101, Issue 2, 2010, Pages 559-567

  Huang, Jia ^a   Yao, Wei Yan ^a   Zhu, Qi ^a   Tu, Shui Ping ^a   Yuan, Fei ^a   Wang, Hua Feng ^a   Zhang, Yong Ping ^a   Yuan, Yao Zong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BID; REGULATOR PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS ASSOCIATED FACTOR 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADULT; AGED; ANIMALS; APOPTOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75649094913     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01396.x     Document Type: Article

References (45)

1. Lohr M. Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol 2006, 3:236-7.
2. Guo X, Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas 2005, 31:13-22.
3. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004, 363:1049-57.
4. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005, 128:1606-25.
5. Gukovskaya AS, Pandol SJ. Cell death pathways in pancreatitis and pancreatic cancer. Pancreatology 2004, 4:567-86.
6. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-811.
7. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3:401-10.
8. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-04.
9. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and-7 in distinct modes. J Biol Chem 2001, 276:27058-63.
10. Karikari CA, Roy I, Tryggestad E. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007, 6:957-66.
11. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
12. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K, Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 2001, 8:613-21.
13. Liston P, Fong WG, Kelly NL. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 2001, 3:128-33.
14. Leaman DW, Chawla-Sarkar M, Vyas K. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J Biol Chem 2002, 277:28504-11.
15. Chung SK, Lee MG, Ryu BK. Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses. Gastroenterology 2007, 132:2459-77.
16. Xia Y, Novak R, Lewis J, Duckett CS, Phillips AC. Xaf1 can cooperate with TNFalpha in the induction of apoptosis, independently of interaction with XIAP. Mol Cell Biochem 2006, 286:67-76.
17. Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk RG. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 2000, 70:113-22.
18. Ng KC, Campos EI, Martinka M, Li G. XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol 2004, 123:1127-34.
19. Lee MG, Huh JS, Chung SK. Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses. Oncogene 2006, 25:5807-22.
20. Byun DS, Cho K, Ryu BK. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 2003, 63:7068-75.
21. Zou B, Chim CS, Zeng H. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology 2006, 131:1835-43.
22. Kempkensteffen C, Hinz S, Schrader M. Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: correlations with pathology and outcome. Cancer Lett 2007, 254:227-35.
23. Fang X, Liu Z, Fan Y. Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor. Int J Cancer 2006, 118:2485-9.
24. Reu FJ, Bae SI, Cherkassky L. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 2006, 24:3771-9.
25. Straszewski-Chavez SL, Visintin IP, Karassina N. XAF1 mediates tumor necrosis factor-alpha-induced apoptosis and X-linked inhibitor of apoptosis cleavage by acting through the mitochondrial pathway. J Biol Chem 2007, 282:13059-72.
26. Mimeault M, Brand RE, Sasson AA, Batra SK. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas 2005, 31:301-16.
27. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20:1218-49.
28. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006, 5:787-96.
29. Shibata T, Noguchi T, Takeno S, Gabbert HE, Ramp U, Kawahara K. Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas. Ann Surg Oncol 2008, 15:3494-502.
30. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277-88.
31. Trauzold A, Wermann H, Arlt A. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001, 20:4258-69.
32. Hinz S, Trauzold A, Boenicke L. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000, 19:5477-86.
33. Scaffidi C, Fulda S, Srinivasan A. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17:1675-87.
34. Gross A, Yin XM, Wang K. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999, 274:1156-63.
35. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005, 5:876-85.
36. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-22.
37. Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 complex. J Biol Chem 2007, 282:26202-9.
38. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22:8581-9.
39. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003, 3:46-54.
40. Shin S, Sung BJ, Cho YS. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-23.
41. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999, 13:239-52.
42. Li F, Ambrosini G, Chu EY. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-4.
43. Burris HA, Moore MJ, Andersen J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized-trial. J Clin Oncol 1997, 15:2403-13.
44. Rothenberg ML, Moore MJ, Cripps MC. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996, 7:347-53.
45. Tu SP, Liston P, Cui JT. Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer. Int J Cancer 2009, 125:688-97.